Schizophrenia Clinical Trials in Hollywood, Florida

14 studies are recruiting for schizophrenia in Hollywood, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia

   The purpose of this clinical trial is to learn whether the investigational drug LTX-001 is safe and well tolerated in adults with a diagnosis of schizophrenia who are having a recent worsening of their symptoms (an acute exacerbation). Additional questions it aims to answer are: * how does the amou…

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   Behavioral Clinical Research, Inc., Hollywood, Florida

   Locations

   10 in total

   Run by

   Leal Therapeutics, Inc

   See if you can join NCT07734493 on ClinicalTrials.gov

2. Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

   The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Research Centers of America ( Hollywood ), Hollywood, Florida

   Locations

   59 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT07686263 on ClinicalTrials.gov

3. 52-week Open Label Safety-Tolerability Study

   Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   CenExel, Hollywood, Florida

   Locations

   23 in total

   Run by

   LB Pharmaceuticals Inc.

   See if you can join NCT07369154 on ClinicalTrials.gov

4. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

   The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.

   Stage

   Phase 3

   Ages

   13 to 17

   Site

   Local Institution - 0119, Hollywood, Florida

   Locations

   38 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07288567 on ClinicalTrials.gov

5. A Study of Brenipatide in Adult Participants With Schizophrenia

   The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment pe…

   Stage

   Phase 2

   Ages

   18 to 55

   Site

   NextPhase Research Florida - Hollywood, Hollywood, Florida

   Locations

   103 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07410507 on ClinicalTrials.gov

6. A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT

   A study to evaluate the safety, tolerability, and PK of an injectable form of KarXT in participants with schizophrenia

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   Research Centers of America ( Hollywood ), Hollywood, Florida

   Locations

   8 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07061288 on ClinicalTrials.gov

7. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

   ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Clinical Site, Hollywood, Florida

   Locations

   42 in total

   Run by

   MapLight Therapeutics

   See if you can join NCT07459647 on ClinicalTrials.gov

8. A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

   The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively

   Stage

   Phase 3

   Ages

   5 to 17

   Site

   Local Institution - 0168, Hollywood, Florida

   Locations

   91 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT07424404 on ClinicalTrials.gov

9. A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

   Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Segal Trials - Larkin Behavioral Health - Inpatient & Early Phase Site, Hollywood, Florida

   Locations

   73 in total

   Run by

   Otsuka Pharmaceutical Development & Commercialization, Inc.

   See if you can join NCT06894212 on ClinicalTrials.gov

10. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

    This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Neurocrine Clinical Site, Hollywood, Florida

    Locations

    57 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT07114874 on ClinicalTrials.gov

11. Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

    The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Neurocrine Clinical Site, Hollywood, Florida

    Locations

    20 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT07227818 on ClinicalTrials.gov

12. NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

    The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Neurocrine Clinical Site, Hollywood, Florida

    Locations

    21 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT06963034 on ClinicalTrials.gov

13. Study of ALTO-101 in Patients With Schizophrenia

    This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition. Additional goals are to assess pharmacokinetic (PK), safety, and tolerabil…

    Stage

    Phase 2

    Ages

    21 to 55

    Site

    Site 5060, Hollywood, Florida

    Locations

    14 in total

    Run by

    Alto Neuroscience

    See if you can join NCT06502964 on ClinicalTrials.gov

14. Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

    This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period o…

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Reviva site, Hollywood, Florida

    Locations

    18 in total

    Run by

    Reviva Pharmaceuticals

    See if you can join NCT05184335 on ClinicalTrials.gov